Skip to main content

Table 3 QLQ-H&N43: Quality of life of patients with head and neck cancer during antineoplastic treatment (n = 63)

From: Health-related quality of life became worse in short-term during treatment in head and neck cancer patients: a prospective study

Quality of Life domains T0 T1 T2 p-value ∆T1-T0
n (%)
∆T2-T1
n (%)
∆T2-T0
n (%)
Mean (SD) Median (p25-p75) Mean (SD) Median (p25-p75) Mean (SD) Median (p25-p75) ≥ ± 10 score points n (%)
Anxiety 38.88 (38.21) 33.33 (0.00–66.66) 35.44 (34.45) 33.33 (0.00–66.66) 32.01 (29.82) 33.33 (0.00–50) 0.662 20 (31.7) 19 (30.2) 21 (33.3)
Body image 19.40 (28.70) 0.0 (0.0–33.33) 19.92 (25.49) 11.11 (0.0–33.33) 24.51 (29.54) 11.11 (0.0–44.44) 0.382 22 (34.9) 21 (33.3) 24 (38.1)
Coughing 30.15 (37.72) 0.0 (0.00–66.66) 33.33 (36.41) 33.33 (0.00–66.66) 34.92 (38.06) 33.33 (0.00–66.66) 0.680 18 (28.6) 21 (33.3) 21 (33.3)
Dry mouth and sticky saliva 33.86 (30.07) 33.33 (0.0–50) 69.84 (29.19) 66.66 (33.33–100) 62.69 (30.48) 66.66 (33.33–100) < 0.001c 43 (68.3) 17 (27.0) 40 (63.3)
Lymphoedema 25.39 (40.03) 0.0 (0.0–33.33) 17.98 (32.69) 0.0 (0.0–33.33) 15.34 (29.22) 0.0 (0.0–33.33) 0.059 8 (12.7) 8 (12.7) 10 (15.9)
Neurological problems 10.58 (24.55) 0.0 (0.0–0.0) 19.57 (33.13) 0.0 (0.0–33.33) 22.75 (34.81) 0.0 (0.0–33.33) 0.001 15 (23.8) 10 (15.9) 17 (27.0)
Trismus or Opening mouth 18.51 (36.30) 0.0 (0.0–0.0) 22.22 (36.41) 0.0 (0.0–33.33) 28.57 (39.19) 0.0 (0.00–66.66) 0.113 10 (15.9) 13 (20.6) 14 (22.2)
Pain in the mouth 28.30 (29.99) 16.66 (0.0–41.66) 36.90 (29.43) 33.33 (8.33–58.33) 32.27 (25.68) 25 (8.33–50) 0.012b 29 (46.0) 12 (19.0) 28 (44.4)
Sexuality 23.54 (35.24) 0.0 (0.0–50) 35.44 (40.87) 0.0 (0.0–66.66) 35.44 (41.63) 0.0 (0.0–66.66) 0.020 26 (41.3) 13 (20.6) 23 (36.5)
Social contact 20.63 (37.59) 0.0 (0.0–33.33) 23.80 (38.99) 0.0 (0.0–66.66) 24.33 (36.02) 0.0 (0.0–66.66) 0.613 12 (19.0) 13 (20.6) 13 (20.6)
Problems with senses 14.55 (24.03) 0.0 (0.0–16.66) 47.35 (33.49) 50 (16.66–66.66) 45.76 (30.37) 50 (16.66–50) < 0.001c 45 (71.4) 18 (28.6) 47 (74.6)
Shoulder Problems 12.16 (22.83) 0.0 (0.0–16.66) 10.31 (21.46) 0.0 (0.0–0.0) 10.58 (23.81) 0.0 (0.0–0.0) 0.627 7 (11.1) 12 (19.0) 11 (17.5)
Skin problems 8.11 (12.33) 0.0 (0.0–11.11) 31.39 (23.74) 33.33 (11.11–44.44) 26.63 (21.07) 22.22 (11.11–44.44) < 0.001c 47 (74.6) 23 (36.5) 41 (65.1)
Social eating 24.60 (31.12) 8.33 (0.0–41.66) 34.65 (27.19) 25 (16.66–50) 30.68 (26.59) 25 (8.33–50) 0.009b 34 (54.0) 14 (22.2) 29 (46.0)
Speech 31.85 (31.59) 20 (6.66–60) 31.21 (33.58) 20 (0.0–60) 33.12 (32.17) 20 (6.66–60) 0.729 15 (23.8) 20 (31.7) 18 (28.6)
Swallowing 30.02 (30.06) 25 (0.0–58.33) 43.78 (30.63) 41.66 (16.66–75.00) 37.56 (29.70) 33.33 (8.33–58.33) 0.014b 31 (49.2) 12 (19.0) 28 (44.4)
Problems with teeth 16.75 (23.51) 0.0 (0.0–33.33) 22.22 (25.32) 11.11 (0.0–33.33) 33.15 (68.12) 33.33 (0.0–33.33) 0.002a 25 (39.7) 22 (34.9) 33 (52.4)
Weight loss 26.45 (36.92) 0.0 (0.0–41.66) 34.92 (40.35) 0.0 (0.0–66.66) 39.78 (40.41) 33.33 (0.0–66.66) 0.004 21 (33.3) 15 (24.2) 26 (41.9)
Problems with wound healing 6.87 (23.30) 0.0 (0.0–0.0) 4.76 (16.78) 0.0 (0.0–0.0) 5.29 (17.15) 0.0 (0.0–0.0) 0.978 4 (6.3) 5 (7.9) 6 (9.5)
  1. P-values followed by letters differed statistically according to the post hoc test at the 5% probability level (Friedman test and Dunn post hoc test ajusted by Bonferroni: a difference between T0 and T2; b difference between T0 and T1; c difference between T0 and T1, and T0 and T2. ∆ T1-T0, ∆ T2-T1 and ∆ T2-T0 ≥ 10 or ≤ −10 score points: clinically significant negative difference